SWITCH PATTERNS AND TOTAL COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIASIS

被引：0
|
作者：
Wu, J. [1 ]
Pelletier, C. [2 ]
Ung, B. [2 ]
Tian, M. [2 ]
Ni, Q. [2 ]
Curtis, J. R. [3 ]
机构：
[1] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA
[2] Celgene Corp, Summit, NJ USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2523
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS23
引用
收藏
页码：S426 / S426
页数：1
相关论文
共 50 条
  • [31] Persistence and failure rates of adalimumab monotherapy in biologic-naive patients with psoriasis: A retrospective study
    Reddy, Shivani P.
    Lin, Elaine J.
    Shah, Vidhi V.
    Wu, Jashin J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (03) : 575 - 577
  • [32] REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Udeze, C.
    Pelletier, C.
    Tian, M.
    VALUE IN HEALTH, 2019, 22 : S888 - S888
  • [33] Apremilast in combination with systemic and biologic therapies for psoriasis treatment
    Ighani, Arvin
    Georgakopoulos, Jorge R.
    Walsh, Scott
    Shear, Neil H.
    Yeung, Jensen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB46 - AB46
  • [34] Real world tumor necrosis factor (TNF) blocker treatment patterns for biologic-naive psoriasis patients in a US managed care population
    Smith, Timothy
    Joyce, Amie
    Fox, Kathleen
    Gandra, Shravanthi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB10 - AB10
  • [35] Real world use of ixekizumab is associated with reductions in concomitant medications among biologic-experienced or biologic-naive patients with psoriasis
    Wu, Jashin J.
    Zhu, Baojin
    Burge, Russel
    Goldblum, Orin
    Choong, Casey
    Edson-Heredia, Emily
    Amato, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB114 - AB114
  • [36] Starting-dose trends over time in biologic-naive and biologic-experienced psoriasis patients initiated on ustekinumab or adalimumab
    Guerin, Annie
    Sundaram, Murali
    Gauthier, Genevieve
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB253 - AB253
  • [37] TREATMENT PERSISTENCE IN PSORIASIS PATIENTS INITIATED ON APREMILAST, ORAL SYSTEMICS, OR BIOLOGIC THERAPIES
    Feldman, S. R.
    Kaura, S.
    Li, S.
    Tencer, T.
    VALUE IN HEALTH, 2017, 20 (09) : A805 - A805
  • [38] TREATMENT PATTERNS OF BIOLOGIC USE IN PSORIASIS PATIENTS IN ENGLAND
    Khalid, J. M.
    Fox, K. M.
    Globe, G.
    Maguire, A.
    Chau, D.
    VALUE IN HEALTH, 2012, 15 (07) : A574 - A574
  • [39] Response to mepolizumab treatment in biologic-naive asthma patients and patients who received omalizumab
    Sasano, Hitoshi
    Harada, Norihiro
    Sato, Yoshihiko
    Sandhu, Yuuki
    Tanabe, Yuki
    Harada, Sonoko
    Jingo, Koichi
    Okuma, Tomoko
    Watanabe, Takayasu
    Kato, Yukari
    Nishimaki, Takayasu
    Abe, Sumiko
    Ueda, Shoko
    Goto, Ai
    Takeshige, Tomohito
    Matsuno, Kei
    Ito, Jun
    Nagaoka, Tetsutaro
    Atsuta, Ryo
    Takahashi, Kazuhisa
    RESPIROLOGY, 2023, 28 : 183 - 184
  • [40] Evaluation of abatacept in biologic-naive patients with active rheumatoid arthritis
    Schiff, Michael
    Bessette, Louis
    CLINICAL RHEUMATOLOGY, 2010, 29 (06) : 583 - 591
12345